Developing a vaccine for human rhinoviruses
Journal Title: Journal of Vaccines & Immunization - Year 2014, Vol 2, Issue 3
Abstract
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute exacerbations of chronic airway diseases. Infections can be life threatening in the latter context however RV -induced common colds have an associated economic cost from loss of productivity due to absence from work or school. There are no appropriate antiviral therapies available and vaccine strategies have failed because of the large number of viral serotypes and the lack of cross-serotype protection generated. Here, approaches past and present for development of a vaccine to these widespread human pathogens are highlighted.
Authors and Affiliations
McLean GR
Keywords
Related Articles
- EP ID EP566691
- DOI 10.14312/2053-1273.2014-3
- Views 76
- Downloads 0
Comparison of the live attenuated mumps vaccine (Miyahara strain) with its preattenuated parental strain
Live attenuated mumps vaccines have been developed by passaging the field isolates in cells that differ from the natural host. To study mumps viral (MuV) attenuation at the genomic level, we compared a live attenuated mu...
An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary...
Events following BCG vaccination during neonatal period and factors that might affect potency and side effects
Introduction: In Sri Lanka, BCG vaccine is given during neonatal period. There are many myths regarding BCG vaccine and sequelae of vaccination are not clearly documented in medical literature. Objectives: Objectives of...
Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardi...
Hospital epidemiology and costs of pertussis in France: A retrospective database analysis
Background: Pertussis vaccination coverage remains unsatisfactory in adults in France and pertussis is the leading cause of death due to bacterial infection in infants up to 3 months of age, whom are most often infected...